Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of Oral E5501 (Avatrombopag) Plus Standard of Care in Adults with Chronic Immune Thrombocytopenia
2011-000830-12Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing E5501 (avatrombopag) plus standard of care with Placebo plus standard of care (2 arms). Started Aug 2011; status: completed.
02
Drugs
avatrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2011-000830-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000830-12.